Qtrex Quantum Ltd. · NASDAQ:QTEX

Qtrex Quantum — Inspira Technologies Oxy B.H.N. — Investor Presentation (July 2022)

47 slides from Qtrex Quantum's investor presentation, July 2022

Slide 2: Forward looking-Statements
Forward looking-Statements This presentation of InspiraTM Technologies Oxy B.H.N. Ltd. (Inspira Technologies or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities law. Words such as “expects,” “intends,” “plans
Slide 3: Investment Highlights
Investment Highlights A novel therapy Forecasting growth Revolutionary early-stage extracorporeal respiratory The potential market for the company is expected to grow support system, intended to rebalance oxygen saturation steadily in the coming years due to the increasing prevalence of levels¹ and
Slide 4: Inspira Cash Management
Inspira Cash Management Company incorporation $12 million $16 million $9.4 million ~$37.4 million Raised prior to IPO: Raised at initial public Warrant exercised at $5.50 Total cash Including funds from offering on NASDAQ per share Israeli Innovation raised to-date Authority Feb.2018 2019 up to Q1-2
Slide 5: Vision: Redefining Artificial Respiration
Redefining Artificial Respiration Vision to impact millions of lives Copyright © 2018-2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved 5
Slide 6: Our mission: an alternative to invasive mechanical ventilation
Our mission is to provide an alternative to invasive mechanical ventilation for acute respiratory patients who continue to deteriorate while being treated with non- invasive ventilation treatment. ▪ Non-invasive ventilation (NIV) - is the delivery of oxygen (ventilation support) via a face mask and
Slide 7: Respiratory Failure: The Unmet Need
Respiratory Failure The Unmet Need
Slide 8: Respiratory Failure - Definition
Respiratory Failure - Definition Respiratory failure is a serious medical condition that Respiratory failure is a serious develops when the lungs cannot get sufficient medical condition that develops oxygen into the blood. Buildup of carbon dioxide can when the lungs cannot get also damage the tissu
Slide 9: Mechanical Ventilation Has Significant Downsides
Mechanical Ventilation for Treating Patients With Acute Respiratory Failure Has Significant Downsides¹ˉ³ MV requires intrusive intubation, coma induction, and can be very traumatic for patients: Potential Risks & Complications High Cost of Treatment • Ventilator-induced lung injury (VILI) • Long hos
Slide 10: Acute Respiratory Failure: Current Treatment Paradigm
Acute Respiratory Failure: Current Treatment Paradigm Acute Respiratory Failure Hypoxemia Hypercarbia Hypoxemia & Hypercarbia Non-Invasive Ventilation¹ RESPIRATORY DETERIORATION • Nasal mask • Oxygen Helmet • Face mask • HFNC (High Flow • Nasal plugs Nasal Cannula) Invasive ventilation² • BIPAP CPAP
Slide 11: Developing a minimally invasive extracorporeal blood oxygenation system
Inspira Technologies is developing a minimally invasive, cost- effective early-stage extracorporeal blood oxygenation system that utilizes a proprietary hemo-protective flow technology to rebalance oxygen saturation levels in order to minimize the need for invasive mechanical ventilation. Copyright
Slide 12: Market Potential
Market Potential • The U.S. Market • Multiple trends propelling the market • COVID-19 and growing medical community experience with extracorporeal respiratory systems is expected to accelerate market adoption
Slide 13: Potential Market Size in the U.S. (Primary Market)
Potential Market Size in the U.S. (Primary Market) The ~633,000 acute respiratory failure patients in the U.S. each year, are Inspira's target population for the ART system1. With current treatments they continue to deteriorate following non-invasive ventilation treatment, are intubated, anesthetize
Slide 14: Multiple Trends Propelling the Market in the Coming Years
Multiple Trends Propelling the Market in the Coming Years U.S. Market is Expected to Grow Steadily – A stable growth is expected Growing geriatric population (Based on invasive mechanical ventilation market – Inspira’s patient population target market) According to estimates published by the WHO, th
Slide 15: Medical Community Experience with ECMO Following COVID-19
Experience Gained by the Medical Community with ECMO Following COVID-19 May Potentially Facilitate Faster Adoption of ARTTM 10 In the last 5 years, 26,582 adults with 11 pulmonary diseases were treated with 22 6 VV-ECMO (international data) as a last resort treatment¹ 23 337 24 25 717 hospitals in t
Slide 17: A New Approach to Minimize the Need for Mechanical Ventilation
A New Approach to Minimize the Need for Mechanical Ventilation Mechanical Ventilation Inspira’s ARTTM System* IV sedation Awake Patient Intubation Cannula Insertion Artificial Respiration Hemo-protective extracorporeal treatment Ventilator Associated Complications Discharge Weaning Discharge *These
Slide 18: About ART
About ART™ Extracorporeal approach A system specifically designed to provide continuous low-flow venous-venous early-stage extracorporeal respiratory support Cannula is designed to draw blood at a rate of 1-1.5L per minute¹ Rebalancing oxygenation saturation levels & CO2 removal O2 saturation level
Slide 19: ART Treatment - Possible Indications
ART™ Treatment - Possible Indications ARTTM may be used for the treatment of acute respiratory failure patients suffering from hypoxemia and hypercarbia or both, who continue to deteriorate while being treated with non- invasive ventilation treatment. Pneumonia Acute Respiratory Distress Syndrome As
Slide 20: The ART System: How does it work?
The ARTTM System How does it work? INSERT WITHDRAW ENRICH CIRCULATE REBALANCE Dual lumen cannula Utilizing hemo-protective Blood is enriched with The enriched blood is The returned enriched inserted into the flow technology, the blood high concentrations of returned to the patient blood rebalances t
Slide 21: The ART Hemo Protective System
THE ARTTM – Hemo Protective System The ART System is a medical device including a replaceable disposable respiratory support unit (kit) for Oxygenator each patient treatment. The ART’s design supports the company’s strategic business Initiation System model to encourage the extension of acute respir
Slide 22: ART System Primary Components
ART™ System Primary Components Dual Lumen Cannula Hemo-Protective Initiation System Flow Pump Component: Component: Component: Autonomous initiation Dual lumen cannula, with Proprietary hemo-protective system for self-priming of small diameter (16-21Fr*) pump; designed to prevent the entire blood ci
Slide 23: ART System Primary Components
ART™ System Primary Components Disposable Respiratory Control unit The HYLA™ Blood Support Unit (kit) Sensor Component: Component: Component: Plug-and-play disposable An algorithm enhanced The HYLA™ blood sensor is cartridge. suitable for digital platform, controls and expected to continuously displ
Slide 24: ART's Innovative Features
ART’s Innovative Features Hemo-protective flow technology aimed to reduce the risks of hemolysis & thrombosis Single insertion point of dual-lumen cannula will potentially be lowering the risk of multiple infections & bleeding Proprietary plug-and-play replaceable disposable unit expected to reduce
Slide 25: ART's Proprietary Hemo-Protective Flow Technology Features
ART’s Proprietary Hemo-Protective Flow Technology Features Blood protection ART’s designed features Hemolysis Thrombosis reduction reduction A unique Low flow-velocity ratio maintained V V throughout blood passage in disposable kit A low-volume oxygenator V Pump head designed for low flow V V Short
Slide 26: ART's Respiratory Support System Potential Benefits
ART's Respiratory Support System Potential Benefits The patient's perspective The clinician's perspective The hospital perspective • Immediate oxygen saturation elevation • Clinicians would be able to offer an • Reduced costs and staff burden • No need for induced coma alternative to mechanical vent
Slide 27: ART System Offers Two Intervention Modalities
ARTTM System Offers Two Intervention Modalities Prevention of mechanical ventilation Shortening mechanical ventilation duration Patients who continue to deteriorate Mechanically ventilated patients would When while being treated with non-invasive be treated with ART shortly following the ventilation
Slide 28: What Differentiates ART from ECMO?
What Differentiates ART from ECMO? ARTTM System ECMO* ART has the potential to prevent invasive ECMO is a salvage therapy mechanical ventilation and its associated long-term damages There is no “plan B ”when a patient is not improving with ECMO ART is designed to allow for early intervention Two sin
Slide 30: Studies Results Highlights and Conclusions
Studies Results Highlights Conclusions ART treatment in hypoxemic swine model, resulted in significant increase of oxygen saturation by 8%-10% A flow of 1 liter per minute, was sufficient to provide a saturation increase of 8-10% Pulmonary artery saturation increase is attributed to ART device activ
Slide 31: Pre-clinical Studies (In-vivo)
Pre-clinical Studies (In-vivo) When: August 2020¹ Test: ART’s ability to rebalance oxygen saturation levels within minutes In 20 out of the 25 hypoxemic 25 hypoxemic events induced, ART treatment³ Where: LAHAV CRO in Israel² events were was provided with a blood flow induced rate of 1 liter per minu
Slide 32: Method
Method In these initial pre-clinical studies the goal was to assess the oxygenation effectiveness of ART system¹ in swine model. Swine model The swine species chosen for the current study is Large-White X Landrace. This breed was chosen due to a well-known resemblance of the anatomy, cardiovascular
Slide 33: Study design
Study design Blood oxygenation and CO2 removal at a flow rate of 1 liter/min was assessed in 20 consecutive observations, with each test, the following steps were repeated: Observation 1 Observation 2 02 03 04 01 Hypoxemia ART Activated Hypoxemia ART Activated induction For 15 minutes induction For
Slide 35: ART Provides Significant Increase In Saturation
ART Provides Significant Increase In Saturation The saturation levels in the pulmonary artery increased on average by 26%, and in the carotid artery by about 8-10% Without ART ART Activated SvO2 & SaO2_ART in OFF mode SvO2 & SaO2_ART in ON mode 0.90 0.85 1.00 0.93 0.80 0.90 0.70 0.80 0.72 0.60 0.70
Slide 36: ART's Contribution to Oxygen Saturation Reviewed Independently From Lung Activity
ART’s Contribution to Oxygen Saturation Should Be Reviewed Independently From the Lung Activity ART increased saturation by 26% in the Pulmonary Artery SvO2 & SaO2 The contribution of ART to saturation should be assessed via 1.00 0.93 saturation measured in the Pulmonary artery; right after ART 0.90
Slide 37: CO2 Removal Via ART Is Significant
CO2 Removal Via ART Is Significant ART contribution to PCO2 decrease is 8.5 mmHg in the pulmonary artery PaCO2 & PvCO2 (mmHg) 45.00 40.53 36.74 38.33 40.00 33.5 35.00 29.83 30.00 27.75 25.00 20.00 15.00 10.00 5.00 0.00 OFF ON OFF ON OFF ON Femoral vein Femoral vein Pulmonary Pulmonary Carotid artery
Slide 39: Market Opportunity By Product
Market Opportunity Market Opportunity ByBy Product* Product* ECLS System ART TM System Targeting Targeting 20 million $700m patient market market Intended use: Intended use: Respiratory support at an early-stage intended to prevent Life Support (Salvation Treatment - Last Resort) the need for Invasi
Slide 40: Go-to-Market Strategy
Go-to-Market Strategy Establishing multiple recurring revenue streams across medical sectors & markets Pursuing regulatory approvals Market penetration and gaining market in key markets: share in collaboration with hospitals 01 United States – Primary market Europe – Secondary Market 03 Market penet
Slide 41: Market Penetration and Gaining Market Share
Market Penetration and Gaining Market Share We have developed a flexible business model to drive global deployment Multiple Healthcare Centers, PRICING MODEL consumer types Medical Services & Medical Device Companies ART system distributed as an OPEX when bundled with disposable respiratory support
Slide 42: Reimbursement Strategy
Reimbursement Strategy Inspira plans to utilize existing CPT Codes using a “New Approach” to an existing procedure Expected to eliminate Aimed to reduce length of complications associated stay & re-admissions with MV Designed to reduced costs Designed to reduce hospital & operational expenses & staf
Slide 43: Targeting Major Milestones 2022-2023
Targeting Major Milestones 2022-2023 We are actively working to establish collaborations with strategic partners which may include: Medical Device or Other Companies, Health Associations, Strategic Agreements for Manufacturing & Distribution 2022 H1-2023 H2-2023 $ The reveal V&V FDA 510(K) Generatio
Slide 44: Experienced Leadership Team
Experienced Leadership Team Prof. Benad Goldwasser, MD, MBA Dagi Ben-Noon, BSc Joe Hayon, MBA Chairman Co-Founder, Director & CEO Co-Founder, Director, President & CFO Multiple well-known industry exits Co-founder of Nano Dimension M&A experience & track record Nasdaq: NNMD - Elscint Technologies -
Slide 45: Scientific Advisory Board
Scientific Advisory Board - Several world-renowned KOL’s Prof. Daniel Brodie Prof. Eddy Fan Dr. Stephan Ledot Dr. Yigal Kasif, MD Intensivist & ECMO Advisor Intensivist & ECMO Advisor Intensivist & ECMO Advisor ECMO Advisor President-elect of the Extracorporeal Life Medical director of the extracorp
Slide 46: Scientific Advisory Board - cont.
Scientific Advisory Board - cont. Dr. Dekel Stavi, MD Dr. Avraham Abutbul, MD Dr. Yael Lichter, MD Dr. Orit Cohen Jacob, MDV Intensivist Advisor ICU Respiratory Advisor Intensivist Advisor Clinical & Research Advisor Has considerable experience in Senior physician at the Medical A director of the Me

Inspira Technologies Oxy B.H.N. — Investor Presentation (July 2022) on 6ix

Qtrex Quantum — Inspira Technologies Oxy B.H.N. — Investor Presentation (July 2022)

Slide 1: Revolutionizing Acute Respiratory Care

Slide 2: Forward looking-Statements

Slide 3: Investment Highlights

Slide 4: Inspira Cash Management

Slide 5: Vision: Redefining Artificial Respiration

Slide 6: Our mission: an alternative to invasive mechanical ventilation

Slide 7: Respiratory Failure: The Unmet Need

Slide 8: Respiratory Failure - Definition

Slide 9: Mechanical Ventilation Has Significant Downsides

Slide 10: Acute Respiratory Failure: Current Treatment Paradigm

Slide 11: Developing a minimally invasive extracorporeal blood oxygenation system

Slide 12: Market Potential

Slide 13: Potential Market Size in the U.S. (Primary Market)

Slide 14: Multiple Trends Propelling the Market in the Coming Years

Slide 15: Medical Community Experience with ECMO Following COVID-19

Slide 16: ART: Early Extracorporeal Respiratory Support

Slide 17: A New Approach to Minimize the Need for Mechanical Ventilation

Slide 18: About ART

Slide 19: ART Treatment - Possible Indications

Slide 20: The ART System: How does it work?

Slide 21: The ART Hemo Protective System

Slide 22: ART System Primary Components

Slide 23: ART System Primary Components

Slide 24: ART's Innovative Features

Slide 25: ART's Proprietary Hemo-Protective Flow Technology Features

Slide 26: ART's Respiratory Support System Potential Benefits

Slide 27: ART System Offers Two Intervention Modalities

Slide 28: What Differentiates ART from ECMO?

Slide 29: Pre-Clinical Studies (In-vivo)

Slide 30: Studies Results Highlights and Conclusions

Slide 31: Pre-clinical Studies (In-vivo)

Slide 32: Method

Slide 33: Study design

Slide 34: Study Results

Slide 35: ART Provides Significant Increase In Saturation

Slide 36: ART's Contribution to Oxygen Saturation Reviewed Independently From Lung Activity

Slide 37: CO2 Removal Via ART Is Significant

Slide 38: Go To Market

Slide 39: Market Opportunity By Product

Slide 40: Go-to-Market Strategy

Slide 41: Market Penetration and Gaining Market Share

Slide 42: Reimbursement Strategy

Slide 43: Targeting Major Milestones 2022-2023

Slide 44: Experienced Leadership Team

Slide 45: Scientific Advisory Board

Slide 46: Scientific Advisory Board - cont.

Slide 47: THANK YOU